Cibeira, María-Teresa

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 458

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Wang, M., Dimopoulos, M. A., Chen, C., Cibeira, M. T., Attal, M., Spencer, A., Rajkumar, S. V., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2008) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 176